Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase

Rhea-AI Filing Summary

Exagen Inc. Chief Financial Officer Jeffrey G. Black reported several equity-based compensation awards and a plan purchase. He received a stock option for 50,000 shares of common stock at $3.16 per share, expiring in 2036 and vesting over time, with potential full vesting upon certain change-in-control terminations.

He was also granted 75,000 restricted stock units, each representing one share of common stock, which vest in four equal annual installments starting on February 21, 2026, subject to continued service and similar change-in-control provisions. In addition, he acquired 1,511 shares of common stock at $3.077 per share through Exagen’s Employee Stock Purchase Plan. Following these grants and the ESPP purchase, he directly held 343,953 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Black Jeffrey G.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option(right to buy)	50,000	$3.16	$158K
Grant/Award	Common Stock	75,000	$3.16	$237K
Grant/Award	Common Stock	1,511	$3.077	$5K

Holdings After Transaction: Stock Option(right to buy) — 60,000 shares (Direct); Common Stock — 342,442 shares (Direct)

Footnotes (1)

1. The securities awarded are in the form of restricted stock units under the issuer's 2019 Incentive Award Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 21, 2026, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control. The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"). Represents shares of common stock purchased through ESPP in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). The option is exercisable as it vests. 25% of the shares subject to the option vest on February 21, 2027, and 1/48th of the total number of shares subject to the option vest at the end of each calendar month thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Black Jeffrey G.

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CA 92081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A(1)		75,000	A	$3.16	342,442	D
Common Stock(2)	02/27/2026		A	V	1,511(3)	A	$3.077	343,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(right to buy)	$3.16	03/12/2026		A		50,000		(4)	03/11/2036	Common Stock	50,000	$3.16	60,000	D

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units under the issuer's 2019 Incentive Award Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 21, 2026, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control.

2. The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP").

3. Represents shares of common stock purchased through ESPP in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

4. The option is exercisable as it vests. 25% of the shares subject to the option vest on February 21, 2027, and 1/48th of the total number of shares subject to the option vest at the end of each calendar month thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.

Remarks:

	/s/ Jeffrey G. Black	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Exagen (XGN) CFO Jeffrey G. Black report?

Jeffrey G. Black reported equity awards and a plan purchase, not open-market trades. He received 50,000 stock options, 75,000 restricted stock units, and bought 1,511 shares through Exagen’s Employee Stock Purchase Plan, increasing his directly held common stock to 343,953 shares.

How many stock options did the Exagen (XGN) CFO receive and on what terms?

He received stock options covering 50,000 shares of Exagen common stock at an exercise price of $3.16 per share. The options expire in 2036 and vest over time, beginning February 21, 2027, with monthly vesting thereafter, subject to continued service and certain change-in-control conditions.

What are the details of the restricted stock units granted to the Exagen (XGN) CFO?

He was granted 75,000 restricted stock units under Exagen’s 2019 Incentive Award Plan, each representing one share of common stock. The RSUs vest 25% on each of the first four anniversaries of February 21, 2026, contingent on continued service, with possible full vesting upon qualifying change-in-control termination.

Did the Exagen (XGN) CFO make any purchases through the Employee Stock Purchase Plan?

Yes. Jeffrey G. Black voluntarily reported acquiring 1,511 shares of Exagen common stock through the Employee Stock Purchase Plan at $3.077 per share. These ESPP purchases were reported as exempt transactions under Rule 16b-3 provisions and increased his directly held common stock position.

How many Exagen (XGN) common shares does the CFO hold after these transactions?

After the reported grants and ESPP purchase, Jeffrey G. Black directly holds 343,953 shares of Exagen common stock. This figure reflects his position following the 75,000-share restricted stock unit grant and the 1,511-share Employee Stock Purchase Plan acquisition disclosed in the filing.

How do vesting and change-in-control terms affect the Exagen (XGN) CFO’s new awards?

Both the 75,000 RSUs and 50,000 stock options vest over multi-year schedules tied to continued service. Each award may become fully vested upon a qualifying termination of employment in connection with a change in control, potentially accelerating his ownership if such an event occurs.